ArticleInternational journal of general medicine2025
Identification of Potential Therapeutic Targets for Sepsis Using Mendelian Randomization and Integrated eQTL/pQTL Analysis.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- EGCG Derivatives Alleviate Diquat-Induced Liver and Gut Damage in Mice by Activating an Antioxidant Pathway and Enhancing Barrier Function.Animals : an open access journal from MDPI · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sepsis significantly contributes to global morbidity, yet effective treatments remain limited. Mendelian randomization (MR), integrated with genetic data, offers promise for uncovering novel therapeutic targets. Methods: We utilized eQTL (eQTLGen) and pQTL (DECODE) data as exposures, and GWAS summaries for sepsis (UK Biobank, FinnGen) as outcomes. GEO datasets (GSE57065, GSE95233) underwent batch correction via PCA clustering using the "sva" R package. Differentially expressed genes (DEGs, |log2FC|>1, adjusted P<0.05) intersected with druggable genes were identified. MR analyses were performed using TwoSampleMR and MR-PRESSO, followed by drug-target predictions using DGIdb. Key genes (BCL6, PTX3, IL7R, BTN3A2, LGALS1) were validated experimentally through qRT-PCR and Western blot in a mouse sepsis model induced by cecal ligation and puncture (CLP). Results: Intersection analyses yielded 398 therapeutic candidates. MR revealed 6 genes and 21 proteins significantly associated with sepsis risk, including protective (eg, HDC, IFI27) and harmful factors (eg, CTSO, BTN3A2). Furthermore, 13 druggable genes correlated with sepsis-related factors, such as BTN3A2 with diabetes, and IL7R, BCL6, PTX3, among others, linked to vitamin D deficiency and cancer. DGIdb identified 34 potential drugs targeting these hub genes, with KEGG and GO analyses highlighting immune regulation and FoxO signaling pathways. qRT-PCR and Western blot confirmed consistent downregulation (BCL6, PTX3, IL7R) and upregulation (BTN3A2, LGALS1) at both mRNA and protein levels in septic mice compared to controls, supporting MR-based predictions. Conclusion: We identified and experimentally validated 6 sepsis-associated genes and 21 proteins, providing crucial insights into potential therapeutic targets and enhancing understanding of the molecular pathogenesis of sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.